A Nanoparticle-Based Immunoassay on Facemasks for Evaluating Neutrophilic Airway Inflammation in COPD Patients

Abstract

Patients with chronic obstructive pulmonary disease (COPD) often experience acute exacerbations characterized by elevated neutrophilic inflammation in the lungs. Currently, this condition is diagnosed through visual inspection of sputum color and volume, a method prone to personal bias and unsuitable for patients who are unable to expectorate spontaneously. In this manuscript, we present a novel approach for measuring and monitoring exhaled myeloperoxidase (MPO), a biomarker of neutrophilic airway inflammation, without the need for sputum analysis. The method involves analyzing an unmodified surgical facemask worn by the patient for 30 min using biosensing decals that transfer antibody-coated nanoparticles. These colloids specifically interact with MPO trapped by the facemask in a dose-dependent manner, enabling the quantification of MPO levels, with a dynamic range up to 3 · 101 µg·mL−1. The proposed diagnostic approach successfully differentiated patients with acute exacerbations from stable patients with 100% sensitivity and specificity. Healthy individuals also showed significantly lower MPO levels compared to COPD patients. Our results suggest that facemask analysis could be a non-invasive diagnostic tool for airway diseases, particularly in patients unable to expectorate.